NASDAQ:NRIX Nurix Therapeutics Q2 2026 Earnings Report $23.98 +0.01 (+0.04%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$23.69 -0.29 (-1.21%) As of 07/2/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nurix Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.73Beat/MissN/AOne Year Ago EPSN/ANurix Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$15.29 millionBeat/MissN/AYoY Revenue GrowthN/ANurix Therapeutics Announcement DetailsQuarterQ2 2026Date7/9/2026TimeBefore Market OpensConference Call DateWednesday, July 8, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Nurix Therapeutics Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)3 hours ago | theglobeandmail.comNurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on ThursdayJuly 2 at 1:10 AM | americanbankingnews.comGoldman Sachs: 300 million jobs will disappearGoldman Sachs predicts 300 million jobs will disappear - and Elon Musk's 'Project Apex' AI supercomputer is accelerating the timeline. A Nobel Prize-winning scientist says what Musk is building could have a greater impact than the internet. Louis Navellier, who flagged Nvidia before its 82,000% run, has identified one company at the center of this buildout. It's 49 times smaller than Tesla and already powers Microsoft, Meta, Amazon, and Google - and he's sharing the name and ticker in a free briefing. | InvestorPlace (Ad)Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership ValueJune 30, 2026 | finance.yahoo.comNurix Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:NRIXJune 26, 2026 | benzinga.comNurix (NRIX) Climbs to 52-Week High — This Deal May Hold the AnswerJune 26, 2026 | finance.yahoo.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology. The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies. Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches. Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponGeneral Mills Is a 5-Star Turnaround Play for Buy and Hold InvestorsCopper Stocks Are Getting a Bigger Spotlight as Gold’s Rally CracksNike Q4 Beat Masks Core Weakness as Analysts Cut Price TargetsIs the Memory Rally Still Alive After the Semiconductor Sell-Off?Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases3 Charts That Could Change the Course of Summer Trading Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
